Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours; a single center, prospective, interventional, non-comparative, open label, phase II study (HEPAR PLUS study)

Date

29 Sep 2019

Session

Proffered Paper – NETs and endocrine tumours

Presenters

Sander Ebbers

Citation

Annals of Oncology (2019) 30 (suppl_5): v564-v573. 10.1093/annonc/mdz256

Authors

A.J.A.T. Braat1, R. van Rooij2, R.C.G. Bruijnen2, M.N.G.J.A. Braat2, F. Wessels2, S. Ebbers1, R.S. van Leeuwaarde3, M. van Treijen3, H.W.A.M. de Jong2, M.G.E.H. Lam2

Author affiliations

  • 1 Radiology And Nuclear Medicine, University Medical Center Utrecht, 3584 CX - Utrecht/NL
  • 2 Radiology And Nuclear Medicine, University Medical Center Utrecht, Utrecht/NL
  • 3 Department Of Endocrinology, University Medical Center Utrecht, Utrecht/NL
More

Resources

Background

The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT. To investigate this hypothesis, a phase II study was initiated to assess effectiveness and toxicity of holmium-166 radioembolization (166Ho-RE) after PRRT with lutetium-177 (177Lu)-DOTATATE.

Methods

The HEPAR PLUS study was a single center, prospective, interventional, non-comparative, open label study. Thirty patients with >3 measurable residual liver metastases according to RECIST 1.1 received 166Ho-RE within 20 weeks after the 4th and last cycle of PRRT with 7.4 GBq 177Lu-DOTATATE. Primary objectives: objective response rate (ORR = complete plus partial response) after three months according to RECIST 1.1 (treatment volume, liver and patient-based analysis). Secondary endpoints included toxicity profile according to CTCAE v4.03 and quality of life assessments according to EORTC QLQ-C30 and GI.NET21 questionnaires.

Results

Three months after PRRT plus 166Ho-RE, liver ORR was 43% according to RECIST 1.1. In patient-based analysis, ORR was 40% according to RECIST 1.1, stable disaese in 50% and three patient (10%) experienced progressive disease (due to progressive lesions or development of new lesions outside the treatment volume). CTCAE grade 3-4 toxicities were limited to abdominal pain (10%), nausea (3%) and fatigue (3%). One related serious adverse event occurred in one patient (3%), fatal radiation induced liver disease. Quality of life assessments showed a temporary non-significant decrease in most scales at three weeks post-treatment and complete resolution three months after treatment.

Conclusions

This was the first prospective study to combine PRRT and 166Ho-RE in metastatic NET. A radiation boost on intrahepatic disease using 166Ho-RE leads to a high objective response rate without significant additional short-term side-effects, and a temporary non-significant decrease in quality of life in well-selected patients.

Clinical trial identification

NCT02067988.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

A.J.A.T. Braat: Non-remunerated activity/ies: Terumo; Non-remunerated activity/ies: BTG; Non-remunerated activity/ies: Sirtex Medical. M.G.E.H. Lam: Honoraria (institution), Non-remunerated activity/ies: Terumo; Advisory / Consultancy, Non-remunerated activity/ies: BTG; Advisory / Consultancy, Non-remunerated activity/ies: Sirtex Medical; Non-remunerated activity/ies: Mirada. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings